Search Results

You are looking at 141 - 150 of 1,415 items for :

  • "carcinoma" x
  • Refine by Access: All x
Clear All
Full access

Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma

Andre P. Fay, Guillermo de Velasco, Thai H. Ho, Eliezer M. Van Allen, Bradley Murray, Laurence Albiges, Sabina Signoretti, A. Ari Hakimi, Melissa L. Stanton, Joaquim Bellmunt, David F. McDermott, Michael B. Atkins, Levi A. Garraway, David J. Kwiatkowski, and Toni K. Choueiri

Recurrent molecular aberrations at the epigenetic, DNA, RNA, and protein levels have been identified in clear cell renal cell carcinoma (ccRCC). 1 Common emerging themes have evolved, including dysregulation of the von Hippel-Lindau ( VHL ) gene

Full access

Investigational Therapies for Metastatic Thyroid Carcinoma

R. Michael Tuttle and R. Leboeuf

HR . A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments] . Cancer 1998 ; 83 : 2638 – 2648 . 3. Patel KN Shaha AR . Poorly differentiated and anaplastic thyroid cancer

Full access

Metastatic Anal Carcinoma: The Role of Radiotherapy

Yi-Jen Chen

Over the past 30 years, the incidence of invasive anal carcinoma in the United States has increased at a rate of roughly 2% per year. 1 Most patients present with locoregionally confined disease; distant metastases often involving liver, lung, or

Full access

Validation of the 8th Edition of the UICC/AJCC Staging System for Nasopharyngeal Carcinoma From Endemic Areas in the Intensity-Modulated Radiotherapy Era

Ling-Long Tang, Yu-Pei Chen, Yan-Ping Mao, Zi-Xian Wang, Rui Guo, Lei Chen, Li Tian, Ai-Hua Lin, Li Li, Ying Sun, and Jun Ma

management and clinical trials. 2 Despite originating from similar cell or tissue lineages, the natural behavior of and therapeutic considerations for nasopharyngeal carcinoma (NPC) are distinct from other epithelial head and neck tumors. Recent advances in

Full access

Survival After Definitive Chemoradiotherapy With Concurrent Cisplatin or Carboplatin for Head and Neck Cancer

Michael Xiang, A. Dimitrios Colevas, F. Christopher Holsinger, Quynh-Thu X. Le, and Beth M. Beadle

Background In 2019, an estimated 65,000 cases of head and neck (H&N) cancer will be diagnosed in the United States, with approximately 14,000 cancer-related deaths. 1 Many cases of locally or regionally advanced H&N squamous cell carcinoma (HNSCC

Full access

Pulmonary Neuroendocrine Carcinomas: Progress and Pitfalls

Gregory P. Kalemkerian

tumors constitute approximately 20% of all lung cancers, with SCLC accounting for 15%, large cell neuroendocrine carcinoma (LCNEC) 2% to 3%, and carcinoid tumors 1% to 2%. Pulmonary neuroendocrine cancers (NECs) are generally categorized by grade: high

Full access

On the Verge: Immunotherapy for Colorectal Carcinoma

David Y. Oh, Alan P. Venook, and Lawrence Fong

? Until recently, only a few immune therapies for solid malignancies were FDA-approved: the cytokines IL-2 and IFN-alpha (for renal cell carcinoma and melanoma); the cell-based therapy sipuleucel-T (for prostate cancer); and the CTLA4-blocking antibody

Full access

HSR19-092: Adjuvant Radiotherapy Is Associated with Improved Overall Survival for Resected Alveolar Ridge Squamous Cell Carcinoma With Adverse Pathologic Features

Corbin D. Jacobs, Daniel J. Rocke, Russel R. Kahmke, Hannah Williamson, Gita Suneja, and Yvonne M. Mowery

Background: Alveolar ridge (AR) squamous cell carcinoma (SCC) is poorly represented on prospective clinical trials. Adjuvant management is extrapolated from more common head and neck SCC, including those with a stronger influence from the human

Full access

Current Concepts in Penile Cancer

Philippe E. Spiess, Simon Horenblas, Lance C. Pagliaro, Matthew C. Biagioli, Juanita Crook, Peter E. Clark, Richard E. Greenberg, and Cesar E. Ercole

penile squamous cell carcinoma (SCC). Risk factors include an uncircumcised phallus, especially in the presence of phimosis and/or poor hygiene, tobacco use, psoriasis treatment with ultraviolet light A to the genital area, and lichen sclerosis. 7 - 10

Full access

CLO19-035: Safety Profile and Adverse Events of Sunitinib as a First-Line Treatment for Advanced/Metastatic Clear-Cell Renal Cell Carcinoma: Pooled Analysis of Randomized Controlled Trials

Tarek Haykal, Babikir Kheiri, Varun Samji, Yazan Zayed, Ragheed Al-Dulaimi, Inderdeep Gakhal, Areeg Bala, Jason Sotzen, Ahmed Abdalla, and Ghassan Bachuwa

Background: Metastatic clear-cell renal cell carcinoma (RCC) is largely incurable, and its treatment remains challenging. Sunitinib, a tyrosine kinase inhibitor, is one of the current standard-of-care options for treatment-naïve patients with